期刊文献+

乳腺癌易感基因1、P53结合蛋白1、DNA损伤检测点介质1在人喉表皮癌细胞中的表达及临床意义

Expression of Breast Cancer Susceptibility Gene l,P53-binding Protein 1,and Mediator of DNA Damage Checkpoint 1 in Human Laryngeal Carcinoma Cells and Its Clinical Significance
原文传递
导出
摘要 目的研究人喉表皮癌细胞系Hep-2中乳腺癌易感基因1(BRCAl)、P53结合蛋白1(53BP1)和DNA损伤检测点介质1(MDC1)的表达及临床意义。方法采用逆转录聚合酶链式反应检测BRCA1、53BP1、MDC1在喉癌细胞系Hep-2中mRNA的表达,同时用免疫印迹法检测蛋白的表达。结果在所检测的人喉癌细胞系Hep-2中BACR1、53BP1、MDC1在基因与蛋白两个水平均有表达。结论 BRCA1、53BP1、MDC1可能在喉癌的发生发展中有一定作用。 Objective To study the expression of breast cancer susceptibility gene l(BRCA1),P53-binding protein 1(53BP1) and mediator of DNA damage checkpoint 1(MDC1) in human laryngeal carcinoma cell line Hep-2 and its clinical significance.Methods In human laryngeal carcinoma cell line Hep-2,the expression of BRCA1,53BP1 and MDC1 mRNA were detected by RT-PCR,and the BRCA1,53BP1 and MDC1 proteins expression were measured with Western blotting.Results The expression of BRCA1,53BP1 and MDC1 genes and proteins were all observed in human laryngeal carcinoma cell line Hep-2.Conclusion The expression of BRCA1,53BP1 and MDC1 is probably related to human laryngeal tumorigenesis.
出处 《华西医学》 CAS 2012年第11期1641-1644,共4页 West China Medical Journal
关键词 喉癌 乳腺癌易感基因1 P53结合蛋白1 DNA损伤检测点介质1 Laryngeal carcinoma Breast cancer susceptibility gene l P53-binding protein 1 Mediator of DNA damage checkpoint 1
  • 相关文献

参考文献3

二级参考文献121

  • 1Parkin D M, Bary F, Ferlay J, et al. Estimating the world cancer burden Globocan 2000 [J]. Int Cancer, 2001,94(2): 153-156.
  • 2Schiller J H, Harrington D, Belani C P, et al. Comparison of four chemotherapy regiments for advanced non small cell lung cancer [J]. N Engl J Med, 2002,346(2):92-98.
  • 3Wachters F M, Wong L S, Timens W, et al. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage Ill/IV NSCLC patients treated with chemotherapy [J ]. Lung Cancer, 2005,50(2) : 211-219.
  • 4Mullan P B, Quinn J E, Gilmore P M, et al. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents [J]. Oncogene, 2001,20 (43) :6123- 6131.
  • 5Husain A, He G, Venkatraman E S, et al. BRCA1 up- regulation is associated with repai-mediated resistance to cisplatin [J]. Cancer Res, 1998,58(6) : 1120-1123.
  • 6Lafarge S, Sylvain V, Ferrara M, et al. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway [J]. Oncogene, 2001,20(45) : 6597-6606.
  • 7Tomlinson G E, Chen T T L, Stastny V A, et al. Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier [J]. Cancer Res, 1998,58 ( 15 ) : 3237-3242.
  • 8Quinn J E, Kennedy R D, Mullan P B, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis [Jl. Cancer Res, 2003,63 (19) : 6221-6228.
  • 9Rosell R, Skrzypski M, Jassem E, et al. BRCAI: a novel prognostic factor in resected non-small-cell lung cancer [J]. PLoS ONE, 2007,2( 11 ) : e1129.
  • 10FerlayJ, Shin HR, Bray F, Forman D, Mathers C etal. Estimatesofworldwide burden of cancer in 2008: GLOBOCAN 2008. IntJ Cancer 2010; 127: 2893-917.

共引文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部